Neuromodulation Market Size, Share, Growth, Trends 2020 to 2027 - Top Companies like Magstim, Soterix Medical, NeuroPace, NeuroSigma, Synapse Biomedical

Neurological disorders such as cerebrovascular diseases, Alzheimer’s disease, and Parkinson's disease can be treated with the help of neuromodulation that is performed by using various devices or infusing drugs. Devices used in neuromodulation involve the application of electrodes to the spinal cord, brain, or peripheral nerves.

The Neuromodulation market was valued at US$ 7,613.45 million in 2019 and is projected to reach US$ 16,333.98 million by 2027; it is expected to grow at a CAGR of 10.3%during 2020–2027.

Download sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPHE100001415/?openpr-10144

Abbott; Boston Scientific Corporation; Medtronic; NeuroPace, Inc.; NeuroSigma, Inc.; NEVRO CORP; Synapse Biomedical Inc.; Soterix Medical Inc; Integer Holdings Corporation; and Magstim are among the key players operating in the neuromodulation market.

These companies focus on partnerships, product launches, and collaborations, among other business strategies, to sustain their market positions. For instance, in September 2020, Boston Scientific announced its WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) Systems for the European market. The portfolio comprises four MRI conditional and Bluetooth-enabled implantable pulse generators (IPGs). The products from this line feature rechargeable and non-rechargeable options, and an access to waveforms that help cover multiple pain areas.

The growth of the neuromodulation market is driven by the factors such as increasing incidence of neurological disorders and growing developments in neuromodulation technology. Further, the rising demand of neurostimulation devices to treat chronic pain offer lucrative opportunities to the global neuromodulation market players. However, the high cost of neuromodulation devices hinders the market growth.

According to a study ‘Incidence and Prevalence of Major Neurologic Disorders,’ published in January 2018, ~36% of elderly have moderate or severe memory impairment in the US. Each year nearly 1.2 million adults are diagnosed with brain disorders, of which 51.3% is due to stroke and 21% due to Alzheimer’s disease. In addition, nearly 135 million people are diagnosed with Parkinson’s disease, traumatic brain injury, and epilepsy each year. Moreover, ~500,000 cases of brain tumor, multiple sclerosis, and amyotrophic lateral sclerosis are reported annually. Therefore, the growing prevalence of neurological disorders is consequently propelling the demand for neuromodulators as these help in relieving neurological symptoms. Furthermore, the rising demand for neurostimulation devices to treat chronic pain.

Chronic pain management helps relieve pain with the use of drugs, therapies, and lifestyle changes. Electrical stimulation devices play a major role in pain management as they are primarily developed for relieving several types of chronic and acute pain.Growing geriatric population, increasing chronic condition prevalence, and sedentary lifestyle are a few of the risk factors that may cause chronic pain. For instance, according to a study published by Arthritis Foundation in 2019, aging population is responsible for the growing prevalence of all types of diseases across the world. The same study stated that1 in 3 people in the US suffers from arthritis each year. Therefore, the rising prevalence of chronic pain is expected to drive the growth of the segment during the forecast period.

The report segments the global neuromodulation market as follows:

By Technology

External (Non-Invasive) Neuromodulation
Respiratory Electrical Stimulation
Transcutaneous Electrical Nerve Stimulation
Transcranial Magnetic Stimulation
Internal Neuromodulation
Deep Brain Stimulation
Sacral Nerve Stimulation
Gastric Electrical Stimulation
Spinal Cord Stimulation
Vagus Nerve Stimulation
By Application

Chronic Pain Management
Failed Back Syndrome
Epilepsy
Tremor
Incontinence
Depression
Dystonia
Gastroparesis
Parkinson’s Disease
Obsessive-Compulsive Disorder
Migraine

Purchase Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPHE100001415/?openpr-10144

Reason To Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the neuromodulation market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global neuromodulation market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.